Antisense Compounds Modulating ANGPTL3 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular and metabolic disorders lack effective options, and angiopoietin-like 3 (ANGPTL3) plays a significant role in lipid metabolism, making it a target for therapeutic intervention.
Innovation Solution
Development of antisense compounds that modulate ANGPTL3 expression using mechanisms such as RNaseH, RNAi, and dsRNA enzymes to inhibit ANGPTL3 expression, thereby reducing triglyceride, cholesterol, and glucose levels, and treating associated diseases like cardiovascular disease and metabolic syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiovascular and metabolic disorders are used, then existing therapeutic options are maintained, but effective treatment outcomes are lacking
Solution Approach 1:
The patent extracts and targets the specific pathogenic factor ANGPTL3 from the complex metabolic disorder system. By developing antisense compounds that specifically bind to and inhibit ANGPTL3 expression, the invention isolates and addresses the key driver of lipid metabolism disorders, thereby improving treatment effectiveness without requiring broad-spectrum therapies
Solution Approach 2:
The antisense compounds serve as intermediary molecules that mediate between the administered therapy and the target ANGPTL3 protein. These compounds translate the therapeutic intent into specific molecular inhibition by binding to ANGPTL3 mRNA and preventing its translation, thus providing a bridge between external treatment and internal pathogenic mechanism
2Reliability
If ANGPTL3 expression is inhibited using antisense compounds, then lipid metabolism pathways are targeted effectively, but new therapeutic mechanisms must be developed
Solution Approach 1:
The patent replaces traditional small-molecule drug mechanisms with nucleic acid-based antisense mechanisms. Instead of using small molecules that must navigate complex pharmacokinetic pathways, the invention employs antisense oligonucleotides that directly target and inhibit ANGPTL3 mRNA translation, substituting a more direct molecular recognition mechanism for conventional drug-protein interactions
Solution Approach 2:
The invention changes the fundamental parameter of therapeutic intervention from protein-level inhibition to nucleic acid-level suppression. By targeting ANGPTL3 at the mRNA level rather than the protein level, the antisense compounds alter the timing and location of therapeutic action, enabling prevention of pathogenic protein synthesis before it occurs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense compounds effectively reduce ANGPTL3 levels, leading to decreased triglyceride, cholesterol, and glucose levels, thereby ameliorating cardiovascular and metabolic diseases by targeting the underlying lipid metabolism pathways.
Implementation Method 1
antisense compounds that modulate ANGPTL3 expression using mechanisms such as RNaseH, RNAi, and dsRNA enzymes
Implementation Method 2
antisense compounds that modulate ANGPTL3 expression using mechanisms such as RNaseH, RNAi, and dsRNA enzymes
Implementation Method 3
antisense compounds that modulate ANGPTL3 expression using mechanisms such as RNaseH, RNAi, and dsRNA enzymes
Implementation Method 4
Once in circulation, TG is hydrolyzed by lipoprotein lipase (LpL) and the resulting free fatty acids can then be taken up by local tissues
Data Source
AI summary
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.